Treatment of multiple myeloma has substantially changed over the past decade with the
introduction of several classes of new effective drugs that have greatly improved the rates …

More than 30 years after its introduction, autologous stem cell transplantation (ASCT)
remains the standard of care for young patients with newly diagnosed multiple myeloma. Not …

The prognostic value of minimal residual disease (MRD) for progression-free survival (PFS)
and overall survival (OS) was evaluated in a large cohort of patients with multiple myeloma …

Purpose Lenalidomide maintenance therapy after autologous stem-cell transplantation
(ASCT) demonstrated prolonged progression-free survival (PFS) versus placebo or …

Flow cytometry has become a highly valuable method to monitor minimal residual disease
(MRD) and evaluate the depth of complete response (CR) in bone marrow (BM) of multiple …

Importance Numerous studies have evaluated the prognostic value of minimal residual
disease (MRD) in patients with multiple myeloma (MM). Most studies were small and varied …

PURPOSE Assessing measurable residual disease (MRD) has become standard with many
tumors, but the clinical meaning of MRD in multiple myeloma (MM) remains uncertain …

Purpose To perform a critical analysis on the impact of depth of response in newly
diagnosed multiple myeloma (MM). Patients and Methods Data were analyzed from 609 …

Multiple myeloma is characterized by underlying clinical and biological heterogeneity, which
translates to variable response to treatment and outcome. With the recent increase in …

Based on the clinical features of myeloma and related malignancies of plasma cells, it has
been possible to generate a model system of myeloma progression from a normal plasma …